| Risk | Potential Impact | Mitigation Strategy | |------|------------------|---------------------| | | Failure to achieve statistically significant cognitive or motor benefit could stall approvals | Adaptive trial designs, enrichment for biomarker‑positive subpopulations (elevated CSF IL‑1β) | | Long‑term safety of chronic NLRP3 inhibition | The inflammasome plays a role in host defense; chronic suppression might predispose to infections or malignancy | Ongoing surveillance in registries; periodic immunologic monitoring (e.g., vaccine response) | | Regulatory pathway ambiguity | No precedent for oral NLRP3 inhibitors in CNS indications | Early engagement with FDA/EMA via Breakthrough Therapy and PRIME designations; leverage existing data from peripheral NLRP3 programs | | Competitive landscape | Multiple companies (e.g., Novartis , Roche ) are pursuing NLRP3 inhibitors; some are entering CNS trials | Speed to market, robust biomarker package, and differentiation through BBB penetration and oral formulation |